Inhibrx Biosciences, Inc. INBX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $161.66M+30.1% | $124.22M-18.9% | $153.09M-17.9% | $186.57M-13.8% | $216.52M+41.9% | ||
| $9.5M+12.6% | $8.44M+12.5% | $7.5M+16.6% | $6.43M-3.3% | $6.65M-9.9% | ||
| $171.34M+29.0% | $132.83M-17.7% | $161.42M-16.8% | $193.96M-13.2% | $223.39M+39.3% | ||
| $3.2M-14.4% | $3.73M-13.3% | $4.31M-11.9% | $4.89M-11.9% | $5.55M-10.5% | ||
| $11.66M+4.8% | $11.12M+5.2% | $10.58M+3.4% | $10.23M+6.9% | $9.57M+7.6% | ||
| 10.2%0.0% | 10.2%0.0% | 10.2%0.0% | 10.2%0.0% | 10.2%-733,799,990% | ||
| $4.38M0.0% | $4.38M-23.7% | $5.74M-15.7% | $6.81M+0.1% | $6.8M-0.4% | ||
| $183.97M+25.6% | $146.48M-17.5% | $177.47M-16.3% | $212.12M-12.6% | $242.64M+34.2% | ||
| $8.76M+47.4% | $5.94M-12.2% | $6.77M-18.3% | $8.29M-6.7% | $8.89M-3.8% | ||
| $2.24M-69.9% | $7.45M+54.1% | $4.84M+25.6% | $3.85M+41.6% | $2.72M-90.9% | ||
| $2.41M+3.5% | $2.33M+3.5% | $2.25M+3.6% | $2.17M+9.9% | $1.97M+23.7% | ||
| $26.51M-21.6% | $33.8M-6.1% | $35.98M-7.6% | $38.94M-10.8% | $43.64M+7.1% | ||
| $174.99M+74.0% | $100.56M+0.6% | $99.92M+0.6% | $99.28M+0.6% | $98.65M— | ||
| $3.5M-15.3% | $4.13M-13.0% | $4.74M-11.2% | $5.34M-9.5% | $5.9M-8.5% | ||
| $5.9M-8.5% | $6.45M-7.7% | $6.99M-7.0% | $7.51M-4.7% | $7.88M-2.1% | ||
| $205M+48.0% | $138.49M-1.5% | $140.64M-2.0% | $143.56M-3.1% | $148.2M+214% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| 120M0.0% | 120M0.0% | 120M0.0% | 120M0.0% | 120M+11,999,900% | ||
| $258.59M+1.7% | $254.18M+1.6% | $250.18M+1.4% | $246.66M+1.1% | $243.89M+1.7% | ||
| -$279.63M-13.6% | -$246.19M-15.4% | -$213.35M-19.8% | -$178.1M-19.2% | -$149.44M-40.8% | ||
| -$21.04M-363% | $7.99M-78.3% | $36.83M-46.3% | $68.56M-27.4% | $94.44M-29.3% | ||
| $183.97M+25.6% | $146.48M-17.5% | $177.47M-16.3% | $212.12M-12.6% | $242.64M+34.2% | ||
| $262K+10.1% | $238K-42.0% | $410K+44.9% | $283K+5.2% | $269K-29.6% | ||
| $186K+5.1% | $177K-75.7% | $727K-0.4% | $730K— | —— | ||
| $186K+5.1% | $177K-75.7% | $727K-0.4% | $730K— | —— | ||
| $4.38M0.0% | $4.38M-23.7% | $5.74M-15.7% | $6.81M+0.1% | $6.8M-0.4% | ||
| $5.05M-8.7% | $5.54M-7.8% | $6M-7.1% | $6.46M-6.4% | $6.9M-5.9% | ||
| $5.05M-8.7% | $5.54M-7.8% | $6M-7.1% | $6.46M-6.4% | $6.9M-5.9% | ||
| $4.38M0.0% | $4.38M-23.7% | $5.74M-15.7% | $6.81M+0.1% | $6.8M-0.4% | ||
| $14.85M0.0% | $14.85M-0.2% | $14.88M-1.5% | $15.11M0.0% | $15.11M+0.1% | ||
| $5.05M-8.7% | $5.54M-7.8% | $6M-7.1% | $6.46M-6.4% | $6.9M-5.9% | ||
| $4.38M0.0% | $4.38M-23.7% | $5.74M-15.7% | $6.81M+0.1% | $6.8M-0.4% | ||
| $2.24M-69.9% | $7.45M+54.1% | $4.84M+25.6% | $3.85M+41.6% | $2.72M-64.8% | ||
| $15.34M-39.9% | $25.53M-5.3% | $26.96M-5.3% | $28.48M-13.1% | $32.77M+9.6% | ||
| $15.34M-39.9% | $25.53M-5.3% | $26.96M-5.3% | $28.48M-13.1% | $32.77M+9.6% | ||
| $2.24M-69.9% | $7.45M+54.1% | $4.84M+25.6% | $3.85M+41.6% | $2.72M-64.8% | ||
| $2.15M— | —— | $703K-50.0% | $1.41M-28.5% | $1.97M— | ||
| $1.49M— | —— | $2.94M0.0% | $2.94M0.0% | $2.94M— | ||
| $1.49M— | —— | $2.94M0.0% | $2.94M0.0% | $2.94M— | ||
| $1.49M— | —— | $2.94M0.0% | $2.94M0.0% | $2.94M— | ||
| $2.94M— | —— | $2.86M0.0% | $2.86M0.0% | $2.86M— | ||
| $6.59M— | —— | $7.99M-8.1% | $8.7M-6.1% | $9.26M— | ||
| $681K— | —— | $1M-15.4% | $1.19M-14.0% | $1.38M— | ||
| $591K+32.2% | $447K-25.3% | $598K-44.3% | $1.07M+74.9% | $614K-2.4% | ||
| $1.49M— | —— | $1.49M0.0% | $1.49M0.0% | $1.49M— | ||
| $180.9M+69.0% | $107.01M+0.1% | $106.91M+0.1% | $106.79M+0.2% | $106.53M+1,224% | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 14.6M+0.2% | 14.6M+0.5% | 14.5M+0.2% | 14.5M0.0% | 14.5M0.0% | ||
| 15M0.0% | 15M0.0% | 15M0.0% | 15M0.0% | 15M0.0% | ||
| 0— | 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | $0.000.0% | ||
| 5M-2.1% | 5.1M+0.4% | 5.1M-0.4% | 5.1M0.0% | 5.1M+2.8% | ||
| $14.85M0.0% | $14.85M-0.2% | $14.88M-1.5% | $15.11M0.0% | $15.11M+0.1% | ||
| $2.14M-61.4% | $5.54M-6.3% | $5.91M-30.0% | $8.44M-2.8% | $8.68M+53.9% | ||
| $8.58M-20.5% | $10.79M-24.0% | $14.2M+8.2% | $13.13M-30.5% | $18.9M+27.7% | ||
| $857K0.0% | $857K— | —— | —— | $857K— | ||
| $236K+113% | $111K-61.2% | $286K-62.9% | $771K+24.0% | $622K-1.6% | ||
| $591K+32.2% | $447K-25.3% | $598K-44.3% | $1.07M+74.9% | $614K-2.4% | ||
| $1.56M-17.2% | $1.88M-16.5% | $2.25M-9.2% | $2.48M+31.3% | $1.89M-5.5% | ||
| $5.79M+26.8% | $4.57M+62.2% | $2.82M+67.4% | $1.68M+16.2% | $1.45M-59.1% | ||
| $5.02M-2.1% | $5.13M+0.4% | $5.11M-0.4% | $5.13M0.0% | $5.13M+2.8% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $120M0.0% | $120M0.0% | $120M0.0% | $120M0.0% | $120M0.0% | ||
| $14.61M+0.2% | $14.58M+0.5% | $14.5M+0.2% | $14.48M0.0% | $14.48M0.0% | ||
| $14.61M+0.2% | $14.58M+0.5% | $14.5M+0.2% | $14.48M0.0% | $14.48M0.0% | ||
| $6.59M— | —— | $7.99M-8.1% | $8.7M-6.1% | $9.26M— | ||
| $681K— | —— | $1M-15.4% | $1.19M-14.0% | $1.38M— | ||
| $0.10.0% | $0.10.0% | $0.10.0% | $0.10.0% | $0.10.0% | ||
| $693K+111% | $328K+9.3% | $300K-22.5% | $387K+1.8% | $380K-18.3% | ||
| $506K+12.9% | $448K-39.1% | $736K-3.9% | $766K-37.4% | $1.22M+90.5% | ||
| $00.0% | $00.0% | $00.0% | $00.0% | $00.0% | ||
| $15M0.0% | $15M0.0% | $15M0.0% | $15M0.0% | $15M0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $1.39M+6.3% | $1.3M+1.4% | $1.29M+5.4% | $1.22M-33.1% | $1.82M+123% | ||
| $2.15M— | —— | $703K-50.0% | $1.41M-28.5% | $1.97M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Inhibrx Biosciences, Inc.'s total assets?
- Inhibrx Biosciences, Inc. (INBX) holds $184.0M in total assets, down 24.2% year over year.
- How much debt does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. carries $180.9M in total debt against -$21.0M of shareholders' equity, a debt-to-equity ratio of 13.39.
- How much cash does Inhibrx Biosciences, Inc. have?
- Inhibrx Biosciences, Inc. holds $161.7M in cash and equivalents.
- Can Inhibrx Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 6.46 — current assets exceed current liabilities.
- Where does Inhibrx Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
